Novel therapies in transplantation

Expert Opinion on Investigational Drugs

Volumn 14, Issue 3, 2005, Pages 295-304

  Jorga, Anamaria ^a   Johnston, Atholl ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Abatacept; Alemtuzumab; CAMPATH; Cyclosporin; Everolimus; FK 778; FTY 720; Immunosuppressants; ISAtx 247; MMF; Mycophenolate sodium; Myfortic; New immunosuppressive drugs; Transplantation

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ABATACEPT; ALEMTUZUMAB; ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; ISATX 247; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORTHOCLONE; POLYCLONAL ANTIBODY; PREDNISOLONE; PROGRAPH; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; AUTOIMMUNE DISEASE; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BRADYCARDIA; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; COUGHING; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DETERIORATION; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG MARKETING; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; ESOPHAGITIS; FEVER; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HEADACHE; HEART TRANSPLANTATION; HERPES ZOSTER; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRICHOSIS; HYPERTRIGLYCERIDEMIA; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PATIENT CARE; PATIENT COMPLIANCE; PEPTIC ULCER; REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; TREMOR; VOMITING; WEIGHT GAIN;

CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION;

EID: 17144389403     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.3.295     Document Type: Review

References (57)

1. KOVARIK JM, BURTIN P: Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin. Emerg. Drugs (2003) 8(1):47-62.
2. VINCENTI F: New monoclonal antibodies in renal transplantation. Minerva Urol. Nefrol. (2003) 55(1):57-66.
3. JORGA A, JOHNSTON A, HOLT DW: Patient management by cyclosporine C2 monitoring. Transplantation (2004) 77 2):323-324.
4. JOHNSTON A, HOLT DW: Immunosuppressant drugs-the role of therapeutic drug monitoring. Br. J. Clin. Pharmacol. (2001) 52 Suppl. 1):61S-73S.
5. JORGA A, HOLT DW, JOHNSTON A: Therapeutic drug monitoring of cyclosporine. Transplant Proc. (2004) 36(Suppl.2):396S-403S.
6. SAYEGH MH, TURKA LA: The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl J. Med. (1998) 338(25):1813-1821.
7. PELLETIER RP, AKIN B, HENRY ML et al.: The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin. Transplant (2003) 17(3):200-205.
8. SALVADORI M, HOLZER H, DE MATTOS A et al.: Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am. J. Transplant. (2004) 4(2):231-236.
9. BUDDE K, CURTIS J, KNOLL G et al.: Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am. J. Transplant. 2004) 4(2):237-243.
10. ASPESLET L, FREITAG D, TREPANIER D et al.: ISA(TX)247: a novel calcineurin inhibitor. Transplant Proc. (2001) 33 1-2):1048-1051.
11. STALDER M, BIRSAN T, HUBBLE RW, PANIAGUA RT, MORRIS RE: In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J. Heart Lung Transplant (2003) 22 12):1343-1352.
12. GREGORY CR, KYLES AE, BERNSTEEN L et al.: Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation (2004) 78 5):681-685.
13. ABEL MD: Phase I evaluation of a novel calcineurin inhibitor ISAtx247. Am. J. Transplant (2003) 1 AD (Abstract).
14. Isotechika press release: final results of Phase IIa kidney transplant trial at American Transplant Congress (2003).
15. ABEL M: Phase II trial results of ISAtx247, a novel calcineurin inhibitor in renal transplantation. Am. J. Transplant. (2004) 3(Suppl. 2):379 (Abstract).
16. DUMONT FJ: ISAtx-247 (Isotechnika/Roche). Curr. Opin. Investig. Drugs (2004) 5(5):542-550.
17. NASHAN B:, CURTIS J, PONTICELLI C, MOURAD G, JAFFE J, HAAS T: Everolimus and reduced-exposure cyclosporine in de novo renal transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation (2004) 78(9) 1332-1340.
18. KAHAN BD, KAPLAN B, LORBER MI et al.: RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation (2001) 71 10):1400-1406.
19. VITKO Š, MARGARGREITER R WW: Everolimus (Certican™) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (2004)
20. MOURAD G:, NASHAN B, CURTIS J et al.: Certican (RAD, everolimus) the proliferation signal, is complementary with reduced dose Neorat based quadruple immunosuppressive regime. A transplant Odyssey. The future is here. Turkey. (2001):S18.1 (Abstract).
21. EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. (2003) 349(9):847-858.
22. KOVARIK JM, KAPLAN B, TEDESCO SH et al.: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 73(6):920-925.
23. KAHAN BD: FTY-720 in combination with RAD: a calcineurin antagonist-free maintenance immunosupression strategy. 2001: A transplant odyssey. The future is here. (2004): S12.5.
24. KAHAN BD:FTY720: from bench to bedside. Transplant Proc. (2004) 36(Suppl. 2):531S-543S.
25. KAHAN BD: Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther. Drug Monit. (2002) 24 1):47-52.
26. BUDDE K, SCHMOUDER RL, BRUNKHORST R et al.: First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. (2002) 13(4):1073-1083.
27. BUDDE K, SCHMOUDER L, NASHAN B et al.: Pharmacodynamics of single doses of the novel immunosuppressant FTY-720 in stable renal transplant patients. Am. J. Transplant. (2003) 3(7):846-854.
28. KAHAN BD, KARLIX JL, FERGUSON RM et al.: Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, Phase I study. Transplantation (2003) 76 7):1079-1084.
29. TEDESCO-SILVA H, MOURAD G, KAHAN BD et al.: FTY720, a novel immunomodulator: efficacy and safety results from the first Phase IIA study in de novo renal transplantation. Transplantation (2004) 77(12):1826-1833.
30. FERGUSON RM, MULGAONKAR S, TEDESCO-SILVA H: FTY-720 with reduced exposure Neoral provides adequate rejection prophylaxis in de novo renal transplant recipients. Transplantation (2002) (Abstract).
31. BIRSAN T, DAMBRIN C, KLUPP J et al.: Effects of the malononitrilamide FK-778 on immune functions in vitro in whole blood from non-human primates and healthy human volunteers. Transpl. Immunol. (2003) 11(2):163-167.
32. SLAUSON SD, SILVA HT, SHERWOOD SW, MORRIS RE: Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay. Immunol. Lett. (1999) 67(3):179-183.
33. DEUSE T, SCHREPFER S, REICHENSPURNER H: Immunosuppression with FK-778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation (2003) 76(11):1627-1629.
34. BILOLO KK, OUYANG J, WANG X et al.: Synergistic effects of malononitrilamides (FK-778, FK-779) with tacrolimus (FK-506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation (2003) 75(11):1881-1887.
35. QI S, ZHU S, XU D et al.: Significant prolongation of renal allograft survival by delayed combination therapy of FK-778 with tacrolimus in nonhuman primates. Transplantation (2003)75 8):1124-1128.
36. VINCENTI F: What's in the pipeline? New immunosuppressive drugs in transplantation. Am. J. Transplant (2002) 2 10):898-903.
37. VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, VANRENTERGHEM Y, PACZEK L: A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation (2003) 75(12):1934-1939.
38. CIANCIO G, BURKE GW, SUZART K et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation (2002) 73(7):1100-1106.
39. VAN HOOFF JP, SQUIFFLET JP, WLODARCZYK Z, VANRENTERGHEM Y, PACZEK L: A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation (2003) 75(12):1934-1939.
40. DUMONT FJ: Alemtuzumab (Millennium/ILEX). Curr. Opin. Investig. Drugs (2001) 2(1):139-160.
41. KNECHTLE SJ: Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr. Transplant (2004) 8(2):106-112.
42. CALNE R: 'Almost tolerance' in the clinic. Transplant Proc. (1998) 30(7):3846-3848.
43. CALNE R, MOFFATT SD, FRIEND PJ et al.: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68(10):1613-1616.
44. KNECHTLE SJ, FERNANDEZ LA, PIRSCH JD et al.: Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery (2004) 136(4):754-760.
45. CIANCIO G, BURKE GW, GAYNOR JJ et al.: The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation (2004) 78(3):426-433.
46. MARCOS A, EGHTESAD B, FUNG JJ et al.: Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 78(7):966-971.
47. TZAKIS AG, KATO T, NISHIDA S et al.: Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. Transplantation (2003) 75(8):1227-1231.
48. TZAKIS AG, TRYPHONOPOULOS P, KATO T et al.: Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation (2004) 77(8):1209-1214.
49. TZAKIS AG, KATO T, NISHIDA S et al.: Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. Transplantation (2003) 75(9):1512-1517.
50. WATSON CJ, FIRTH J, BRADLEY JR et al.: Campath 1H (alemtuzumab) in renal transplantation: 5 year comparative follow up. Transplantation (2004) 78(2):55 (Abstract).
51. BASU A: Reversal of acute cellular rejection (ACR) using the monoclonal antibody Campath 1H. Tranplantation 4AD. (Abstract)
52. HALE G: Alemtuzumab in stem cell transplantation. Med. Oncol. (2002) 19(Suppl.):S33-S47.
53. CALNE RY: The future of organ transplantation: from the laboratory to the clinic. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1409):767-771.
54. DUMONT FJ: Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. (2004) 6(3):318-330.
55. BARTLETT AS, McCALL JL, AMERATUNGA R et al.: Costimulatory blockade prevents early rejection, promotes lymphocyte apoptosis, and inhibits the upregulation of intragraft interleukin-6 in an orthotopic liver transplant model in the rat. Liver Transpl. (2002) 8(5):458-468.
56. DONG VM, YUAN X, COITO AJ et al.: Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation (2002) 73(8):1310-1317.
57. NASHAN B: Co-stimulation blockade with LEA29Y in renal transplant: improved renal function and CV metabolic profile at 6 months compared with cyclosporine. Am. J. Transplant. (2004) 4 Suppl. 8):441.